Comparative Pharmacology
Head-to-head clinical analysis: CLINDA DERM versus EVOCLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDA DERM versus EVOCLIN.
CLINDA-DERM vs EVOCLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
None Documented
None Documented
2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment.
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic